|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM229522572 |
| 003 |
DE-627 |
| 005 |
20231224082337.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2013 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2013.05.021
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0765.xml
|
| 035 |
|
|
|a (DE-627)NLM229522572
|
| 035 |
|
|
|a (NLM)23892544
|
| 035 |
|
|
|a (PII)S1521-6616(13)00171-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Eberhardson, Michael
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis
|
| 264 |
|
1 |
|c 2013
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 12.11.2013
|
| 500 |
|
|
|a Date Revised 17.09.2013
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Leukapheresis removes circulating leukocytes en route to the target organ. Hitherto unspecific matrixes have been used to remove leukocytes in inflammatory bowel disease (IBD). This report describes a novel selective leukapheresis column based on chemokine-chemokine receptor interaction. We found an increased expression of the gut homing chemokine receptor CCR9 on CD14(+) monocytes and on CD3(+) T lymphocytes from IBD patients. Biologically active CCL25 was coupled to a Sepharose matrix and demonstrated to selectively remove CCR9-expressing cells leaving other cell populations largely unaffected. A patient with active ulcerative colitis, was subjected to CCL25-column leukapheresis. Four days after treatment, he experienced clinical improvement and stable disease improvement ensued. The study illustrates that specific cells can be targeted using high affinity interactions, i.e., CCL25-CCR9 interactions to remove pathogenic gut-homing cells. Leukapheresis using the bCCL25 column should be investigated in a clinical phase I trial of patients with inflammatory bowel disease
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Apheresis
|
| 650 |
|
4 |
|a CCL25
|
| 650 |
|
4 |
|a CCR9
|
| 650 |
|
4 |
|a Chemokines
|
| 650 |
|
4 |
|a Inflammatory bowel disease
|
| 650 |
|
4 |
|a Leukapheresis
|
| 650 |
|
7 |
|a CC chemokine receptor 9
|2 NLM
|
| 650 |
|
7 |
|a CCL25 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Chemokines, CC
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a Receptors, CCR
|2 NLM
|
| 700 |
1 |
|
|a Marits, Per
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jones, Martina
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jones, Petra
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Karlen, Per
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Karlsson, Mats
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cotton, Graham
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Woznica, Kerry
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Maltman, Beatrice
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Glise, Hans
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Winqvist, Ola
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 149(2013), 1 vom: 23. Okt., Seite 73-82
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:149
|g year:2013
|g number:1
|g day:23
|g month:10
|g pages:73-82
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2013.05.021
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 149
|j 2013
|e 1
|b 23
|c 10
|h 73-82
|